Online citations, reference lists, and bibliographies.
← Back to Search

ALS Clinical Trials

A. Chiò, A. Canosa, S. Gallo, S. Cammarosano, C. Moglia, G. Fuda, A. Calvo, M. Gabriele
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Objective: To assess the effect of eligibility criteria in amyotrophic lateral sclerosis (ALS) clinical trials on the representativeness of the enrolled population. Methods: Patients enrolled in 8 placebo-controlled clinical trials in our ALS center from 2003 to 2008 were compared 1) to the patients included a prospective epidemiologic register (Piemonte and Valle d'Aosta register for ALS, PARALS) in the same period and 2) the subset of PARALS patients who met the usual criteria for inclusion in clinical trials (PARALS-ct) (definite, probable, probable laboratory-supported ALS; age between 18 and 75 years; disease duration <36 months; vital capacity at diagnosis ≥70%; score ≥3 at the items swallowing and respiratory insufficiency at the Amyotrophic Lateral Sclerosis Functional Rating Scale–revised scale; riluzole therapy). Results: A total of 164 patients were enrolled in 8 different clinical trials. The PARALS cohort included 813 patients, of whom 539 (66.3%) met the entry criteria for clinical trials. Patients enrolled in clinical trials were different from both epidemiologic cohorts, since they were younger, had a longer diagnostic delay, and were more likely to have a spinal onset, and to be men. Tracheostomy-free survival was significantly longer in the group of patients enrolled in clinical trials (median survival time, trial patients, 3.9 years [95% confidence interval (CI) 3.4–4.4]; PARALS, 2.6 [2.4–2.8]; PARALS-ct, 2.9 [2.7–3.1]). Conclusions: Patients enrolled in clinical trials do not satisfactorily represent the ALS population; consequently, the findings of ALS trials lack of external validity (generalizability). Efforts should be made to improve patients' recruitment in trials, particularly enrolling incident rather than prevalent cases.
This paper references
Recruitment and participation in clinical trials: sociodemographic, rural/urban, and health care access predictors. Cancer Detect Prev 2006;30:24–33
CR Baquet (1980)
10.1212/WNL.43.7.1316
The natural history of amyotrophic lateral sclerosis
S. Ringel (1993)
10.1016/0022-510X(95)00154-T
Prognosis of amyotrophic lateral sclerosis and the effect of referral selection
Ju Ruey-Jiuan Lee (1995)
Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between
O O’Toole (1995)
10.1001/ARCHNEUR.57.8.1171
Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study.
B. J. Traynor (2000)
10.1136/jnnp.74.9.1258
Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000
B. Traynor (2003)
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
R. Miller (2003)
10.1001/JAMA.291.22.2720
Participation in cancer clinical trials: race-, sex-, and age-based disparities.
Vivek Murthy (2004)
Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and
O Oapostoole (2004)
10.1136/jnnp.2005.083402
Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities
A. Chiò (2006)
10.1016/J.CDP.2005.12.001
Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors.
C. Baquet (2006)
10.1016/j.jns.2006.06.027
Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: A population-based study
S. Zoccolella (2006)
10.1513/PATS.200701-009GC
Population issues in clinical trials.
Z. Mosenifar (2007)
10.1136/jnnp.2007.117788
Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004
O. O'Toole (2007)
10.1212/01.wnl.0000269676.07319.09
Phase II/III randomized trial of TCH346 in patients with ALS
R. Miller (2007)
Why we have failed to achieve neuroprotection in Parkinson’s disease
CW Olanow (2008)
10.3109/17482960902803432
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
V. Meininger (2009)
10.1212/01.wnl.0000343008.26874.d1
Epidemiology of ALS in Italy
A. Chiò (2009)
10.3109/17482960903486083
Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis
M. Sanjak (2010)
10.1136/jnnp.2009.175984
Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy
A. Chiò (2010)
10.3109/17482961003610853
The sex ratio in amyotrophic lateral sclerosis: A population based study
Zita-Rose Manjaly (2010)
10.1212/WNL.0b013e3181ed9e7c
Lithium carbonate in amyotrophic lateral sclerosis
A. Chiò (2010)
10.3109/17482960903545334
Guidelines for preclinical animal research in ALS/MND: A consensus meeting
A. Ludolph (2010)
10.1111/j.1460-9568.2010.07260.x
The neurobiology of amyotrophic lateral sclerosis
A. Bento-Abreu (2010)
10.3109/14653240903300682
Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial.
C. Tarella (2010)
10.1136/jnnp.2010.235952
Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study
A. Chiò (2011)
10.3109/17482968.2010.502940
The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials
E. Beghi (2011)
10.1002/mus.21851
Repeated courses of granulocyte colony‐stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study
A. Chiò (2011)
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicentre study. Muscle Nerve 2011;43:189–195
A Chiò (2011)
PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study
A Chiò (2011)
MD, advisory committee); Department of Neurology
O Sassone
Ospedale di Alba (C. Cavestro, MD, site investigator
MD, site investigator); Department of Neurology
M Gionco
Ospedale di Vercelli (P. Santimaria, MD, site investigator); Department of Neurology
Doriguzzi Bozzo
MD, site investigator); Department of Neurology
Aou S Department Of Neurology
Scientific Institute of Veruno (F. Pisano, MD, advisory committee); Department of Neurology
Clinica Maugeri
MD, site investigator); Department of Neurology
Ospedale Department Of Neurology
MD, site investigator); Department of Neurology
N Nasuelli



This paper is referenced by
10.1016/j.expneurol.2020.113491
Introduction to spasticity and related mouse models
Frederique Wieters (2021)
10.3233/JAD-201081
Modifiable Barriers for Recruitment and Retention of Older Adults Participants from Underrepresented Minorities in Alzheimer’s Disease Research
K. Indorewalla (2021)
10.2196/28766
A Road Map for Remote Digital Health Technology for Motor Neuron Disease.
R. V. van Eijk (2021)
10.1007/s00415-020-09751-1
Prognostic role of slow vital capacity in amyotrophic lateral sclerosis
A. Calvo (2020)
10.3389/fnmol.2020.00093
P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis
C. Ruiz-Ruiz (2020)
10.3389/fnins.2020.00334
Neurovascular Unit Dysfunction and Neurodegenerative Disorders
Xing Yu (2020)
10.1001/jamaneurol.2020.0421
Improving Access to Clinical Trials for Amyotrophic Lateral Sclerosis Treatment.
M. Vijayaraghavan (2020)
10.1016/j.artmed.2020.101879
A novel method for predicting the progression rate of ALS disease based on automatic generation of probabilistic causal chains
M. Ahangaran (2020)
10.1111/ene.14287
Plateaus in amyotrophic lateral sclerosis progression: results from a population‐based cohort
R. Vasta (2020)
10.1080/21678421.2020.1788092
TRICALS: creating a highway toward a cure
R. V. van Eijk (2020)
10.1159/000502863
The Reconstructed Cohort Design: A Method to Study Rare Neurodegenerative Diseases in Population-Based Settings
G. Logroscino (2020)
10.3389/fphys.2020.00063
Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review
Sandra Carrera-Juliá (2020)
10.1080/21678421.2019.1634736
Implications of spirometric reference values for amyotrophic lateral sclerosis
R. V. van Eijk (2019)
10.1080/21678421.2018.1556698
Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial
R. Bedlack (2019)
10.1212/WNL.0000000000006855
Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
R. V. van Eijk (2019)
10.1136/bmjopen-2018-028525
Using telehealth in motor neuron disease to increase access to specialist multidisciplinary care: a UK-based pilot and feasibility study
Esther V Hobson (2019)
10.1177/1740774519858914
Design and analysis of a clinical trial using previous trials as historical control
D. Schoenfeld (2019)
10.3389/fnins.2019.01310
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
R. Mejzini (2019)
10.1007/s00415-019-09427-5
Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study
R. V. van Eijk (2019)
10.3389/fnins.2019.00135
Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions
Vincent Grollemund (2019)
10.13028/A4T2-5Q35
Compact Cas9s and Their Natural Inhibitors for Genome Editing
Alireza Edraki (2019)
The Environmental Epidemiology of Amyotrophic Lateral Sclerosis in Europe
J. Rooney (2018)
10.1093/jnen/nly040
DNA Damage Response and Repair, DNA Methylation, and Cell Death in Human Neurons and Experimental Animal Neurons Are Different
L. Martin (2018)
10.1371/journal.pone.0195821
Referral bias in ALS epidemiological studies
G. Logroscino (2018)
10.1186/s12883-018-1208-z
Using automated electronic medical record data extraction to model ALS survival and progression
Alex G. Karanevich (2018)
10.1080/21678421.2017.1418001
A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials
I. Daghlas (2018)
10.1016/S1474-4422(18)30404-6
Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Giancarlo Marco Benoît Emma Foad Ahmed Fares Solomon Weldege Logroscino Piccininni Marin Nichols Abd-Allah Abde (2018)
10.1007/s00415-018-8778-y
Riluzole and other prognostic factors in ALS: a population-based registry study in Italy
J. Mandrioli (2018)
10.1101/294231
Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach
R. Kueffner (2018)
10.1136/jnnp-2016-314495
The changing picture of amyotrophic lateral sclerosis: lessons from European registers
O. Hardiman (2017)
10.1080/21678421.2016.1270325
Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study
A. Fasano (2017)
10.1080/21678421.2017.1353098
Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*
B. Hamidou (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar